Anda belum login :: 23 Nov 2024 03:59 WIB
Home
|
Logon
Hidden
»
Administration
»
Collection Detail
Detail
Effect of escitalopram on hot flash interference: a randomized, controlled trial
Oleh:
Carpenter, Janet S.
;
Guthrie, Katherine A.
;
Larson, Joseph C.
;
Freeman, Ellen W.
Jenis:
Article from Journal - ilmiah internasional
Dalam koleksi:
Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 97 no. 06 (Jun. 2012)
,
page 1399-1404.
Topik:
GYNECOLOGY
;
Menopause
;
hot flashes
;
night sweats
;
selective serotonin reuptake inhibitor
Ketersediaan
Perpustakaan FK
Nomor Panggil:
F02.K.2012.02
Non-tandon:
1 (dapat dipinjam: 0)
Tandon:
tidak ada
Lihat Detail Induk
Isi artikel
Objective To estimate the effect of escitalopram (10–20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s) A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s) After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s) The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s) Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s) Escitalopram (10–20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables.
Opini Anda
Klik untuk menuliskan opini Anda tentang koleksi ini!
Kembali
Process time: 0.015625 second(s)